Skip to content
Cour Pharmaceuticals
  • Careers
  • Contact Us
  • Linkedin
  • Twitter
  • Home
  • About
    • The COUR Team
    • Medical & Science Partners
    • Product Development
  • Pipeline
    • CNP-101/TAK-101 (Celiac Disease)
    • CNP-201 (Peanut Allergy)
    • CNP-104 (Primary Biliary Cholangitis)
    • CNP-T1D (Type 1 Diabetes)
    • CNP-MYG (Myasthenia Gravis)
    • CNP-ITP (Immune Thrombocytopenia Purpura)
  • Technology
    • COUR Nanoparticle Platform
    • Immune Reprogramming
  • Therapeutic Areas
    • Autoimmune Diseases: Celiac
    • Food & Environmental Allergies: Peanut Allergy
    • Rare Diseases: Primary Biliary Cholangitis
    • Autoimmune Diseases: Type 1 Diabetes
    • Rare Diseases: Myasthenia Gravis
    • Rare Diseases: Immune Thrombocytopenia Purpura
    • Protein Replacement: Gene Therapy
  • Partners & Collaborators
  • Media & Publications
    • Press Releases
    • Scientific Publications
  • Videos
    • Technology
    • Autoimmune Disease
    • Food and Environmental Allergies
    • Gene Therapy

COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model

  •   
Cour Pharmaceuticals

Archives: News

COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model

COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis

CBRE Arranges Expansion Lease for Cour Pharmaceuticals

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy

Specificity of the T Cell Response to Protein Biopharmaceuticals

Protein biopharmaceuticals (BPs) have revolutionized the treatment of many diseases and their […]

U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)

FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals

Today, COUR Pharma announced the U.S. Food and Drug Administration accepted its […]

COUR’s intracellular T-cell reprograming leads to a reduction to anti-drug and neutralizing antibodies

Posts navigation

1 2 Next
  • info@CourPharma.com

Connect

Connect

Pipeline

  • Pipeline
  • CNP-101/TAK-101 (Celiac Disease)
  • CNP-201 (Peanut Allergy)
  • CNP-104 (Primary Biliary Cholangitis)
  • CNP-T1D (Type 1 Diabetes)
  • CNP-MYG (Myasthenia Gravis)
  • CNP-ITP (Immune Thrombocytopenia Purpura)

Technology

  • Technology
  • COUR Nanoparticle Platform
  • Immune Reprogramming
  • Videos
  • Technology
  • Autoimmune Disease
  • Food and Environmental Allergies
  • Gene Therapy
  • Media & Publications
  • Press Releases
  • Scientific Publications
  • Corporate Deck

Therapeutic Areas

  • Therapeutic Areas
  • Autoimmune Diseases: Celiac
  • Food & Environmental Allergies: Peanut Allergy
  • Rare Diseases: Primary Biliary Cholangitis
  • Autoimmune Diseases: Type 1 Diabetes
  • Rare Diseases: Myasthenia Gravis
  • Rare Diseases: Immune Thrombocytopenia Purpura
  • Protein Replacement: Gene Therapy
close ×
CNP-101/TAK-101 (Celiac Disease) CNP-201 (Peanut Allergy) CNP-104 (Primary Biliary Cholangitis) CNP-T1D (Type 1 Diabetes) CNP-MYG (Myasthenia Gravis) CNP-ITP (Immune Thrombocytopenia Purpura)
  • About
  • Partners & Collaborators
  • Careers
  • Contact Us
  • Sitemap
Website by Axxiem
© Copyright . All Right Reserved
Privacy | Terms of Use